Etanercept (Enbrel®) ELISA
- SKU:
- TM09005
- Bulk Pricing:
-
- Buy 5 - 20 and get 5% off
- Buy 21 - 30 and get 10% off
- Buy 31 - 50 and get 15% off
- Buy 51 or more – call for best pricing
The cookie settings on this website are set to 'allow all cookies' to give you the very best experience. Please click Accept Cookies to continue to use the site.
ImmunoGuide® Enzyme immunoassay (ELISA) test kit for the determination of free Etanercept (Enbrel®) in serum and plasma.<br><br>
The drug Etanercept (trade name Enbrel®) is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. Etanercept binds specifically to human tumor necrosis factor alpha (TNF-α) and blocks its interaction with cell surface TNF receptors. It was possible to show that the surveillance of circulating Etanercept concentration during maintenance therapy represents a direct and/or indirect factor for immunogenicity and some other side effects. In this context, identification of biomarkers for (non-)response and risk factors for adverse drug reactions that might be related to serum concentrations and maintaining the effective concentration of Etanercept in order to potentially avoid some side effects with a reliable method might be beneficial. For research use only, not for use in diagnostic procedures.
ImmunoGuide® Enzyme immunoassay (ELISA) test kit for the determination of free Etanercept (Enbrel®) in serum and plasma.<br><br>
The drug Etanercept (trade name Enbrel®) is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. Etanercept binds specifically to human tumor necrosis factor alpha (TNF-α) and blocks its interaction with cell surface TNF receptors. It was possible to show that the surveillance of circulating Etanercept concentration during maintenance therapy represents a direct and/or indirect factor for immunogenicity and some other side effects. In this context, identification of biomarkers for (non-)response and risk factors for adverse drug reactions that might be related to serum concentrations and maintaining the effective concentration of Etanercept in order to potentially avoid some side effects with a reliable method might be beneficial. For research use only, not for use in diagnostic procedures.